TargAnox, a Boston-based drug startup focused on oxidative stress, has raised $5.1 million in Series A funding, according to Xconomy. Ascent Biomedical Ventures led the round, and was joined by Partners Innovation Fund.
Related posts:
Yahoo’s $1.1 billion planned purchase of blogging site Tumblr is the largest exit of a pre-public venture-backed New York-based company
Author : mboslet
It’s that time of the year when every VC (or, well, most VCs) secretly pulls up Forbes’ Midas list and,
Author : mahendra
The Michigan Venture Capital Association said 29 venture capital firms now do business in the state and contributed to the
Author : mboslet
MassChallenge said it selected 128 startups for its 2013 MassChallenge Accelerator Program. The companies come from eighteen states and 11
Author : mboslet
Over a 10-year period ending in 2011, Harvard Business School professor Noam Wasserman researched roughly 10,000 founders, finding that by
Author : connieloizos
Welcome! Join the peHUB community to make connections, share your opinion, and follow your favorite authors. It's quick and easy.
Click here to get started!
